Marion v. Searle
Executive Summary
In a Sept. 25 complaint, Cardizem manufacturer asked Kansas City, Mo. Federal Court for injunction against comparative ads with "false, misleading and deceptive" claims that Searle's Calan dosage is 240 mg per day, whereas Cardizem's is 180 mg twice daily. Marion argues that Calan is prescribed at "higher than 240 mg per day" while Cardizem's dosage is 90 mg b.i.d.
You may also be interested in...
Cochlear’s Osia System Receives Expanded FDA Clearance For Use In Younger Children
Kids ages 5 and up now can benefit from Cochlear’s Osia implant and sound processor, indicated for hearing loss, mixed hearing loss and single-sided sensorineural deafness.
MAISI: Navigating The 'Valley Of Death' In Medtech Research Translation
Translating research from proof of concept to clinical investigations is a difficult hurdle to overcome. To succeed, researchers need to design their technology for industrial standard manufacturing early on, Anne Vanhoestenberghe, director for the Manufacture of Active Implants and Surgical Instruments (MAISI), told Medtech Insight.
Incyte Hopes To Augment Immune/Inflammation Pipeline With Escient Deal
Incyte will pay $750m to acquire privately held Escient and its first-in-class oral antagonists of Mas-related G protein-coupled receptors X2 and X4.